|
Artemesia
The following is information from an article called “Chinese Herb Cures Cancer” by Dr. Robert Jay R
Rowen in the publication “Second Opinion” – in the May 2002 issue.
Call 1-800-728-2288 to order this publication. Artemesia is also known as wormwood if you decide to research it. You
can also go to http://www.artemisia.net/activ.htm
for more information on this. I believe this report was published in the
November 2001 issue of the journal "Life Sciences." Artemesia is a
plant that grows in Southeast that Dr. Rowen has used in the past to treat intestinal parasites.
It is also considered a safe malaria treatment. When Dr. Rowen
discovered a report by Drs. Henry Lai and Narenda Singh,
bioengineering professors at the University of Washington, that
indicated that the herb "might provide a safe, non-toxic, and inexpensive
alternative for cancer patients", he started using it with cancer
patients. Dr. Lai and his colleague, Dr.
Singh, had found its use dramatically killed breast-cancer cells and leukemia cells
while leaving normal breast cells and white blood cells
unscathed. According to
Lai, it is believed to work because when artemisinin or any of its
derivatives comes into contact with iron, a chemical reaction ensues,
spawning charged atoms that chemists call free radicals. Cells need iron
to replicate DNA when they divide, and since cancer is characterized by
out-of-control cell division, cancer cells have much higher iron
concentrations than do normal cells. What Lai did was to pump up
cancer cells with even more iron and then introduce artemisinin to
selectively kill them. Lai theorizes that more aggressive cancers such
as pancreatic and acute leukemia — which are characterized by more
rapid cell division and thus higher iron concentrations — may respond
even better.
Dr. Rowen also reported on an article
that appeared about a year ago in a major cancer journal
demonstrating significant artemisinin anticancer activity in a wide
variety of laboratory cultured cancer cells. Cancers resistant to common chemotherapy drugs showed no
resistance to artemisinin. (International
Journal of Oncology 18; 767-773, 2001 by Efferth, et al.)
One of the patient's Dr. Rowen worked
with was a
47-year-old female with stage-4 breast cancer with mets to the spine..
She used IPT, high-dose nutritional
therapy, dietary changes, dendritic cell vaccine, multi-step oxygen
therapy, and more. All of her symptoms regressed, but the CT showed no
change. When artemisinin derivatives were added, greater results were
obtained.
A Dr. Hoang of Hanoi, Vietnam, reports that 50-60 percent of 400 cancer patients have
achieved long-term remission utilizing artemisinin together with a
comprehensive integrative cancer strategy.
Among
these patients is a 47 -year-old female who, presented with terminal
liver cancer from hepatitis B and abdominal ascites (massive swelling
from liver failure) , was just days or weeks from death. Today;
two-and-a-half years later, she is alive and well with no signs of any
disease!
Dr.
Singh is currently following many cancer patients. While not reporting
remissions or apparent cures, he says all patients are responding and
have at least stabilized. He has found no type of cancer unresponsive
to artemisinin derivatives in his studies.
Dr.
Hoang recommends treatment for two years. Cancer could be like the
malaria parasite. If just one cell remains, it can find its way back.
Thus, as in malaria, although the parasite is cleared in a few days,
prolonged treatment best prevents relapse.
This
treatment is said to be non-toxic, so you can continue taking it
indefinitely with no expected side effects, though it does depend on
the form of Artemesia one uses.
There
are three common Artemesia derivatives - Artesunate is water soluble and
may be the most active and the least toxic, but it has the shortest
life within the body. Artemether is oil or lipid soluble and has the
longest half-life. It also has the most toxicity (but this is related
to rather high dosages, which are not necessary. Its big advantage is
that it can cross the blood-brain barrier to reach cancers in the
nervous system. Artemisinin is the active parent compound of the
plant. It has an intermediate half-life, is very safe, and also can
cross the blood-brain barrier.
The
first two are slightly altered semi-synthetic derivatives of
artemisinin, the concentrated and purified active agent. Dr. Singh
reports that a combination of the forms may be the very best treatment
due to these different properties (based on a lab experiment). Thus,
he feels the best preparation will contain artemisinin and artemether
to provide a dose of 0.5-2 mg/Kg of each form once daily before bed
(away from any residual iron left in the stomach from the evening
meal). Dr. Hoang used 500 mg twice daily of oral artemisinin with good success.
The
product is best taken on an empty stomach with some natural fat to
enhance absorption. Any iron present from residual food may neutralize
the peroxides. Milk is one of the few foods with minimal iron. Whole
milk, cottage cheese, or yogurt have ample fat to enhance absorption.
Additionally, Dr. Rowen stated that he adds cod liver oil
(for its omega-S and vitamin D) and conjugated linoleic acid (CLA) to
this therapy. He says that, with the exception of patients
very near death, taking artemisinin or derivatives have stabilized,
improved, or remitted every cancer patient he has followed. Medical literature
also seems to suggest that oxygenating the system might make the
products effective. Administration of certain chemotherapy agents (IPT), which
kill cells through free radical mechanisms, is another option.
Artemesia herb products are not the same as the concentrated
forms of the derivatives described above. The highest
concentration of artemisinin (the active agent) in the raw herb in
best of conditions does not even get beyond one-half percent. Dr. Singh tested some products, finding perhaps only 10-20 percent
of anti-cancer activity against cultured cancer cells compared to pure
artemisinin. Allergy Research Group (800-545-9960) distributes a
high-grade artemisinin confirmed by independent lab analysis, so this
is the one Dr. Rowen recommended.
Please note: Dr. Rowen warns that this is not a singular
therapy and should be used in
conjunction with a comprehensive cancer management strategy, together
with the help of an integrative medicine physician or an open-minded
oncologist.
For more information, contact Lai at
206-543-1071 or hlai@u.washington.edu.
For more information on the journal Life Sciences, check the Web at: http://www.elsevier.com/locate/lifescie.
We will provide additional information on
this therapy as we have time to research it.
|